UPDATE: UBS Starts Obalon Therapeutics (OBLN) at Buy

October 31, 2016 7:55 AM EDT
Get Alerts OBLN Hot Sheet
Price: $11.42 +1.24%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade OBLN Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
(Updated - October 31, 2016 10:43 AM EDT)

UBS initiated coverage on Obalon Therapeutics (NASDAQ: OBLN) with a Buy rating and a price target of $21.

Analyst Matt Miksic said, "We are initiating coverage with a Buy rating and $21 target. We think Obalon's FDA PMA indication and differentiated randomized clinical data position the company to capture share and drive adoption in the large and expanding obesity market, initially targeting ~55-60 mil adult patients in the U.S. with a BMI of 30-40. We see the company as uniquely positioned with defensible competitive advantages to penetrate and develop a new market exceeding $2 bil over time."

For an analyst ratings summary and ratings history on Obalon Therapeutics click here. For more ratings news on Obalon Therapeutics click here.

Shares of Obalon Therapeutics closed at $13.80 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities

UBS

Add Your Comment